Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Dr. Chris Vinnard's 2013 HIV Treatment Update


Published on

Dr. Chris Vinnard provided this update on HIV/AIDS care and treatment at the March 14, 2013 Philadelphia EMA Ryan White Planning Council meeting.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Dr. Chris Vinnard's 2013 HIV Treatment Update

  1. 1. Christopher Vinnard, MD MPH MSCEAssistant Professor of MedicineDivision of Infectious Diseases & HIV MedicineDrexel University College of Medicine
  2. 2. A new report of a cure...
  3. 3.  Infant exposure to HIV was confirmed through review of maternal HIV antibody and plasma viral load testing Infant infection was documented by plasma viral load testing ART (Combivir + Nevirapine) initiated in the infant at 30 hours of age Persistence of HIV following treatment discontinuation was assessed using plasma viral load, proviral DNA, and HIV antibody testing Ultrasensitive assays done at age 24 and 26 months CROI 2013
  4. 4.  Infant infection was confirmed by positive HIV DNA and RNA testing on 2 separate blood samples obtained on 2nd day of life 3 additional plasma viral load tests on day 7, 12, and 20 were positive, before reaching undetectable levels at age 29 days Plasma HIV RNA remained undetectable between months 1 through 26, despite discontinuation of ART at age 18 months
  5. 5.  Ultrasensitive methods found a single copy of HIV RNA in plasma at age 24 months Replication-competent virus was not detected following co-culture of 22 million purified resting CD4+ T cells Plasma viral load, PBMC DNA, and HIV- specific antibodies remained undetectable with standard clinical assays
  6. 6. What about the first patient curedof HIV infection?
  7. 7. New approaches to treatment: Targeting the CCR5 Receptor
  8. 8. “When to start treatment?” New recommendations
  9. 9.  Benefit to the patient  AIDS defining events  Cancers  All cause mortality Benefit to the patient’s partner  ART was 96% effective in reducing transmission between discordant couples
  10. 10. A new one-pill-once-daily regimen
  11. 11. A new indication for antiretroviral therapy
  12. 12.
  13. 13.  Risk Evaluation and Mitigation Strategy Manage known or potential serious risks with a drug or biological product FDA sometimes determines that a REMS is needed in order for the benefits to outweigh the risks of an approved drug REMS may include: Medication Guide, Patient Package Insert, communication plan, and other elements to assure safe use
  14. 14. New treatments (and new drug-druginteractions) for hepatitis C co-infection
  15. 15.  ~30% if HIV-infected individuals in the U.S. are co-infected with hepatitis C Chronic hepatitis C infection is a leading cause of liver disease and mortality in HIV- infected patients HIV/hepatitis C co-infected patients are at greater risk for liver disease and death, compared with hepatitis C patients without HIV infection
  16. 16. Telaprevir + PegIFN/Ribavirin Boceprevir + PegIFN/RibavirinPegIFN/Ribavirin PegIFN/Ribavirin
  17. 17.  Telaprevir  NRTI backbone plus either raltegravir, efavirenz, atazanavir/ritonavir, etravirine, or riplivirine  With efavirenz, increase dose of telaprevir Boceprevir  NRTI backbone plus raltegravir Wait...  New treatments on the horizon for 2014
  18. 18.  New report of a cured patient New research towards a “functional cure” New guidelines for “when to start” therapy in different patient populations New one-pill-once-daily treatment regimen New indication for antiretroviral therapy  Pre-exposure prophylaxis New hepatitis C treatments, and new drug- drug interactions with antiretroviral therapy
  19. 19. Thank you!